Merck & Co., Inc. MRK
HEALTHCARE · DRUG MANUFACTURERS - GENERALi
Market dataready · fetched 2026-11-06T21:26:49.061Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-13
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:18:47.915544228Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-06T21:23:52.568975+00:00
Merck & Co., Inc. options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 152.46 | 31.0% | 4.3% | 141.12 | 35.4% | 4.4% |
| 25Δ | 151.45 | 31.1% | 3.8% | 142.32 | 35.2% | 3.8% |
| 30Δ | 150.45 | 31.2% | 3.3% | 143.24 | 36.6% | 3.4% |
| 35Δ | 149.54 | 31.6% | 2.9% | |||
| 40Δ | 148.70 | 31.9% | 2.5% | 145.36 | 33.0% | 2.3% |
| 45Δ | 147.86 | 31.7% | 2.2% | 146.21 | 33.0% | 2.0% |
| 50Δ | 147.04 | 31.6% | 1.9% | 147.06 | 33.3% | 1.7% |
| 55Δ | 146.21 | 32.4% | 1.6% | 147.90 | 33.1% | 1.4% |
| 60Δ | 145.35 | 33.0% | 1.4% | 148.77 | 33.0% | 1.2% |
| 65Δ | 144.59 | 31.8% | 1.1% | 149.69 | 33.2% | 1.0% |
| 70Δ | 143.85 | 30.0% | 0.9% | 150.60 | 32.6% | 0.8% |
| 75Δ | 142.81 | 31.2% | 0.7% | 151.49 | 31.6% | 0.6% |
| 80Δ | 140.91 | 36.8% | 0.7% | 152.39 | 30.7% | 0.4% |
20Δ
- Pseudo strike
- 152.46
- IV
- 31.0%
- B/E move
- 4.3%
- Pseudo strike
- 141.12
- IV
- 35.4%
- B/E move
- 4.4%
25Δ
- Pseudo strike
- 151.45
- IV
- 31.1%
- B/E move
- 3.8%
- Pseudo strike
- 142.32
- IV
- 35.2%
- B/E move
- 3.8%
30Δ
- Pseudo strike
- 150.45
- IV
- 31.2%
- B/E move
- 3.3%
- Pseudo strike
- 143.24
- IV
- 36.6%
- B/E move
- 3.4%
35Δ
- Pseudo strike
- 149.54
- IV
- 31.6%
- B/E move
- 2.9%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 148.70
- IV
- 31.9%
- B/E move
- 2.5%
- Pseudo strike
- 145.36
- IV
- 33.0%
- B/E move
- 2.3%
45Δ
- Pseudo strike
- 147.86
- IV
- 31.7%
- B/E move
- 2.2%
- Pseudo strike
- 146.21
- IV
- 33.0%
- B/E move
- 2.0%
50Δ
- Pseudo strike
- 147.04
- IV
- 31.6%
- B/E move
- 1.9%
- Pseudo strike
- 147.06
- IV
- 33.3%
- B/E move
- 1.7%
55Δ
- Pseudo strike
- 146.21
- IV
- 32.4%
- B/E move
- 1.6%
- Pseudo strike
- 147.90
- IV
- 33.1%
- B/E move
- 1.4%
60Δ
- Pseudo strike
- 145.35
- IV
- 33.0%
- B/E move
- 1.4%
- Pseudo strike
- 148.77
- IV
- 33.0%
- B/E move
- 1.2%
65Δ
- Pseudo strike
- 144.59
- IV
- 31.8%
- B/E move
- 1.1%
- Pseudo strike
- 149.69
- IV
- 33.2%
- B/E move
- 1.0%
70Δ
- Pseudo strike
- 143.85
- IV
- 30.0%
- B/E move
- 0.9%
- Pseudo strike
- 150.60
- IV
- 32.6%
- B/E move
- 0.8%
75Δ
- Pseudo strike
- 142.81
- IV
- 31.2%
- B/E move
- 0.7%
- Pseudo strike
- 151.49
- IV
- 31.6%
- B/E move
- 0.6%
80Δ
- Pseudo strike
- 140.91
- IV
- 36.8%
- B/E move
- 0.7%
- Pseudo strike
- 152.39
- IV
- 30.7%
- B/E move
- 0.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 26.09% | |
| 25.20% | |
| 25.66% | |
| 29.22% | |
| 24.91% | |
| 28.81% | |
| 26.50% | |
| 42.07% | |
| 32.74% | |
| 28.11% | |
| 32.52% | |
| 31.46% | |
| 28.43% | |
| 28.10% | |
| 26.54% | |
| 27.05% | |
| 27.88% | |
| 27.52% | |
| 27.31% | |
| 27.08% | |
| 29.96% | |
| 29.64% | |
| 30.04% | |
| 27.20% | |
| 28.85% | |
| 28.78% | |
| 28.56% | |
| 28.24% | |
| 24.70% | |
| 27.26% | |
| 28.39% | |
| 29.46% | |
| 32.39% | |
| 28.52% | |
| 29.80% | |
| 28.65% | |
| 30.49% | |
| 29.06% | |
| 28.06% | |
| 30.00% | |
| 30.85% | |
| 30.33% | |
| 31.77% | |
| 32.74% | |
| 34.03% | |
| 35.06% | |
| 36.67% | |
| 39.39% | |
| 38.91% | |
| 40.28% | |
| 43.10% | |
| 42.45% | |
| 45.98% | |
| 39.70% | |
| 44.23% | |
| 43.98% | |
| 47.12% | |
| 35.32% | |
| 31.96% |
Drug Manufacturers - General
NVO
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in…
More →NVS
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
More →OGN
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine,…
More →PFE
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company…
More →SNY
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The…
More →ABBV
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
More →